Breaking News

China To Introduce COVID-19 Vaccine In September 2020

One of the vaccines undergoing clinical trials will likely be put into use in China from September 2020 for health workers and widely available from the beginning of 2021.

China could have a vaccine against the COVID-19 pandemic and be ready for emergency use from September this year and become widely available early next year, a leading Chinese public health expert said.

This is the first time a Chinese official has made an estimate of the development time of the COVID-19 vaccine, which is believed to be the key to stopping the global pandemic.

The U.S. Food and Drug Administration says it will take at least a year before the country gets a vaccine, while the World Health Organization (WHO) says it will take 12 - 18 months to get the vaccine.

Gao Fu, head of the China Centers for Disease Control and Prevention, said on Thursday that the vaccine is currently in the second or third clinical trial phase that could respond to a wave of outbreaks. Monday.

In addition, China also has three vaccines that have just completed the first phase of testing.

"We are leading the development of the COVID-19 vaccine and it will be ready for use by September." 
Gao said.

These vaccines can be used for specific groups of people, such as health care workers.

Recently, in the race to find a vaccine against the global pandemic, there was the participation of Oxford University.
Oxford University research leader Dr. Sarah Gilbert expressed hope that 1 million doses would be ready for use by September.

US modern biotechnology company Moderna began clinical trials of the world's first vaccine in March with the mRNA vaccine. Another US company, Inovio Enterprises, launched its first human DNA vaccine test last month.

Three vaccines developed by Chinese companies and researchers have passed the first test phase to ensure safety and earlier this month began the second phase, involving hundreds to More than 1,000 volunteers tested their effectiveness and researchers assessed the vaccination dose.

The trio includes the Cansino Biological I Adenovirus vaccine and Beijing-based Biotechnology Institute in Tianjin, two inactivated vaccines developed by Wuhan Institute of Biological Products and Research & Sinovac development in Beijing.

No comments